Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites

被引:13
作者
Mestecky, Jiri
机构
[1] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
关键词
human immunodeficiency virus type-1 (HIV-1); mucosal immunity; IgA; AIDS; antibodies;
D O I
10.1016/j.jri.2006.05.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infection with the human immunodeficiency virus-1 (HIV-1) must be considered as a primarily mucosal disease. On a worldwide basis, the absolute majority of HIV infections occur through mucosal surfaces of the genital and intestinal tracts, and the earliest and most dramatic immunologic alterations are induced by the virus in mucosal tissues. However, individual compartments of mucosal components of the immune system display remarkable differences with respect to dominant antibody isotypes, virus phenotypes, densities and origins of cells involved in innate and specific immunity, presence or absence of inductive sites, and routes of immunizations that induce humoral and cellular responses. In this regard, the mucosal immune system of the female and male genital tracts exhibit several features which are distinct from other mucosal tissues, including dominance of the IgG isotype, local as well as pronounced systemic origin of antibodies, the absence of organized lymphoepithelial inductive sites and limited Immoral responses stimulated by local antigen administration. Furthermore, it is evident that, irrespective of the route of infection, HIV-1 induces easily detectable IgG but not IgA specific antibody responses. These differences must be considered in the design of protective vaccines against infection with HIV and other agents of sexually transmitted diseases. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 50 条
  • [21] Genital and Oral Mucosal Immune Response Against HIV-1 in Exposed Uninfected Individuals
    Hasselrot, Klara
    CRITICAL REVIEWS IN IMMUNOLOGY, 2009, 29 (05) : 369 - 377
  • [22] A RAPID, DIRECT TEST FOR ZIDOVUDINE SUSCEPTIBILITY IN CLINICAL ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) FROM INFECTED CHILDREN
    LAN, Y
    JAPOUR, AJ
    KIM, S
    WELLES, SL
    CRUMPACKER, CS
    COOPER, E
    ALATTAR, I
    MCINTOSH, K
    CLINICAL AND DIAGNOSTIC VIROLOGY, 1995, 3 (03): : 259 - 271
  • [23] Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus
    Khattar, Sunil K.
    Palaniyandi, Senthilkumar
    Samal, Sweety
    LaBranche, Celia C.
    Montefiori, David C.
    Zhu, Xiaoping
    Samal, Siba K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (02) : 504 - 515
  • [24] DNA-plasmids of HIV-1 induce systemic and mucosal immune responses
    Asakura, Y
    Lundholm, P
    Kjerrström, A
    Benthin, R
    Lucht, E
    Fukushima, J
    Schwartz, S
    Okuda, K
    Wahren, B
    Hinkula, J
    BIOLOGICAL CHEMISTRY, 1999, 380 (03) : 375 - 379
  • [25] Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
    Colado Simao, Andrea Name
    Victorino, Vanessa Jacob
    Morimoto, Helena K.
    Vissoci Reiche, Edna Maria
    Panis, Carolina
    CURRENT HIV RESEARCH, 2015, 13 (02) : 143 - 150
  • [26] INTEGRATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 DNA INVITRO
    FARNET, CM
    HASELTINE, WA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (11) : 4164 - 4168
  • [27] Strong T cell type-1 immune responses to HIV-1 Tat(1-72) protein-coated nanoparticles
    Cui, ZR
    Patel, J
    Tuzova, M
    Ray, P
    Phillips, R
    Woodward, JG
    Nath, A
    Mumper, RJ
    VACCINE, 2004, 22 (20) : 2631 - 2640
  • [28] Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment
    Bongertz, Vera
    Ouverney, E. Priscilla
    Fernandez, Saada Chequer
    Grinsztejn, Beatriz
    Veloso, Valdilea
    Couto-Fernandez, Jose C.
    Pilotto, Jose H.
    Morgado, Mariza G.
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2007, 102 (07): : 817 - 825
  • [29] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION OF NEURAL XENOGRAFTS
    CVETKOVICH, TA
    LAZAR, E
    BLUMBERG, BM
    SAITO, Y
    ESKIN, TA
    REICHMAN, R
    BARAM, DA
    DELCERRO, C
    GENDELMAN, HE
    DELCERRO, M
    EPSTEIN, LG
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (11) : 5162 - 5166
  • [30] STUDIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) PROTEASE INHIBITORS .3. STRUCTURE-ACTIVITY RELATIONSHIP OF HIV-1 PROTEASE INHIBITORS CONTAINING CYCLOHEXYLALANYLALANINE HYDROXYETHYLENE DIPEPTIDE ISOSTERE
    SAKURAI, M
    HIGASHIDA, S
    SUGANO, M
    HANDA, H
    KOMAI, T
    YAGI, R
    NISHIGAKI, T
    YABE, Y
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1994, 42 (03) : 534 - 540